全部所有文章
UBI總裁王長怡博士獲邀代表參加於華盛頓舉辦之美台經濟合作會議，向美智庫報告台灣於生物與化學製藥領域之優勢及選擇台灣之原因
United Biomedical, Inc. (UBI) of Hauppauge, New York USA announced today that Chang Yi Wang, Ph.D., Chief Executive Officer of UBI, presented at a conference on May 6, 2004, in Washington, D.C. hosted by the US-Taiwan Business Council, The Brookings Institute, and the Center for Strategic and International Studies entitled: The Taiwan Presidential Elections: Political, Economic, & Security Implications. Her presentation, Reasons to Choose Taiwan, addressed some of Taiwan's essential needs in the biopharma area in order to retain its competitive edge and attract further investments as well as highlight some of Taiwan's greatest assets. These include its government policies to promote the biotech and pharma industry, its strong democratic and legal institutions and its diligent, entrepreneurial, and well educated human resources.
About UBI
UBI, headquartered in Hauppauge, NY on Long Island with subsidiaries in Taiwan and China, is a privately held biopharmaceutical company developing immunotherapeutic, and immunodiagnostic products for human and veterinary use. The company manufactures immunodiagnostic kits for the blood screening market, including tests for HIV, hepatitis C, and a kit for SARS, as well as FMD immunodiagnostics, and manufactures a wide variety of pharmaceuticals through “UBI Asia,” a joint venture with major investors from the Republic of China.